Shares of Strides Pharma Ltd. surged 10% to a record high of ₹1,025 on Monday, November 3, extending gains for the fourth consecutive session. The stock has rallied 26% in the past four trading days and is now up nearly sevenfold from its 2023 lows.

Trading volumes also spiked sharply, with around 23 lakh shares changing hands, compared with the 30-day average of 80,000 shares.

The Strides Pharma stock is now trading ex-OneSource, making it a pure-play generic pharmaceuticals business.

Brokerage firm DAM Capital maintained its 'Buy' rating on the stock with a price target of ₹1,250, implying a potential upside of 34% from current levels.

The brokerage said Strides' focus on profitability and cash generation over topline growth, driven by strong execution, differentiates it from other I

See Full Page